Nkarta Inc

33 articles with Nkarta Inc

• Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

  11/12/2021

  Nkarta, Inc. today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs.

• Nkarta Reports Third Quarter 2021 Financial Results and Business Update

  11/10/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the third quarter ended September 30, 2021.

• Nkarta to Participate at Upcoming Investor Conferences - Nov 04, 2021

  11/4/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences.

• MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

  10/28/2021

  MaxCyte, Inc. today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

  10/7/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced NKX019 and NKX101 clinical development program updates.

• Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

  10/1/2021

  Nkarta, Inc. today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.

• Nkarta to Participate at Upcoming Investor Conference

  9/14/2021

  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:

• Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

  8/12/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2021.

• Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

  7/14/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it has signed a lease agreement for a facility to support research and development and future commercial manufacturing of Nkarta’s cell therapy pipeline.

• Nkarta to Present at Upcoming Investor Conference

  6/16/2021

  Nkarta, Inc. today announced its participation at this upcoming investor conference:

• Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

  6/14/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization Board of Directors for the 2021-2022 term.

• Nkarta Announces June 2021 Investor Conference Schedule

  5/25/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at this upcoming investor conference:

• Nkarta Reports First Quarter 2021 Financial Results and Business Progress

  5/13/2021

  Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2021.

• CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

  5/6/2021

  Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities

• Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

  4/28/2021

  Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study NKX019 in patients with relapsed or refractory B cell malignancies.

• Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

  3/25/2021

  Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Interim top-line data from NKX101 clinical trial expected by end of 2021

• Nkarta Announces February and March 2021 Investor Conference Schedule

  2/17/2021

  Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference February 26, 2021 Fireside chat presentation: 1:40 p.m. ET Cowen 41 st Annual Health Care Conference March 3-4, 2021 No presentation

• 

  Nkarta Treats First Patient in Phase I Trial for Relapsed/Refractory AMLS and MDS

  11/13/2020

  Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.

• Nkarta Reports Third Quarter 2020 Financial Results

  11/12/2020

  First patientdosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromes